# Cigna Group (CI)

Informational only - not investment advice.

CIK: 0001739940
SIC: 6324 Hospital & Medical Service Plans
SIC breadcrumb: [Finance, Insurance, And Real Estate](/division/H/) > [Insurance Carriers](/major-group/63/) > [SIC 6324 Hospital & Medical Service Plans](/industry/6324/)
Latest 10-K filed: 2026-02-26
SEC page: https://www.sec.gov/edgar/browse/?CIK=1739940
Filing source: https://www.sec.gov/Archives/edgar/data/1739940/000173994026000006/ci-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-26 · accession 0001739940-26-000006 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001739940.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 274,900,000,000 USD | 2025 | verified |
| Net income | 5,957,000,000 USD | 2025 | verified |
| Assets | 157,919,000,000 USD | 2025 | verified |
| Net margin | 2.17% | 2025 | computed |
| Operating margin | 3.35% | 2025 | computed |
| Revenue YoY | +11.24% | 2025 | computed |
| ROE | 14.28% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

Peer groups: [Managed care and health insurers](/compare/managed-care/) · SIC 6324 Hospital & Medical Service Plans

No market price, no rating, no forecast on this site. Not investment advice.

## Peer comparisons including CI

- Managed care and health insurers: [peer review](/compare/managed-care/) · [market-risk page](/compare/managed-care/risk/)

### Peer percentile fingerprint

| Ratio | CI | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | 2.2% | 1.0% | 78 | 10 |
| Operating margin | 3.3% | 1.3% | 78 | 10 |
| Revenue growth | 11.2% | 12.2% | 11 | 10 |
| ROE | 14.3% | 5.9% | 100 | 10 |
| ROA | 3.8% | 2.3% | 78 | 10 |
| Liabilities / equity | 2.78 | 2.43 | 56 | 10 |
| Current ratio | 0.85 | 1.50 | 11 | 10 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 6324 Hospital & Medical Service Plans, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 274900000000 | USD | 2025 | 2026-02-26 |
| Net income | 5957000000 | USD | 2025 | 2026-02-26 |
| Assets | 157919000000 | USD | 2025 | 2026-02-26 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-26. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001739940.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 39,838,000,000 | 41,806,000,000 | 48,650,000,000 | 153,566,000,000 | 160,401,000,000 | 174,069,000,000 | 180,518,000,000 | 195,265,000,000 | 247,121,000,000 | 274,900,000,000 |
| Net income |  |  |  |  |  |  |  | 5,164,000,000 | 3,434,000,000 | 5,957,000,000 |
| Operating income | 3,088,000,000 | 3,942,000,000 | 4,160,000,000 | 8,077,000,000 | 8,153,000,000 | 7,941,000,000 | 8,450,000,000 | 8,536,000,000 | 9,417,000,000 | 9,200,000,000 |
| Diluted EPS | 7.19 | 8.77 | 10.54 | 13.44 | 22.96 | 15.75 | 21.41 | 17.39 | 12.12 | 22.18 |
| Operating cash flow | 4,026,000,000 | 4,086,000,000 | 3,770,000,000 | 9,485,000,000 | 10,350,000,000 | 7,191,000,000 | 8,656,000,000 | 11,813,000,000 | 10,363,000,000 | 9,601,000,000 |
| Dividends paid |  |  |  | 15,000,000 | 15,000,000 | 1,341,000,000 | 1,384,000,000 | 1,450,000,000 | 1,567,000,000 | 1,611,000,000 |
| Share buybacks | 139,000,000 | 2,725,000,000 | 342,000,000 | 1,987,000,000 | 4,042,000,000 | 7,742,000,000 | 7,607,000,000 | 2,284,000,000 | 7,034,000,000 | 3,621,000,000 |
| Assets |  | 61,759,000,000 | 153,226,000,000 | 155,774,000,000 | 155,451,000,000 | 154,889,000,000 | 143,885,000,000 | 152,761,000,000 | 155,881,000,000 | 157,919,000,000 |
| Liabilities |  | 47,999,000,000 | 112,154,000,000 | 110,395,000,000 | 105,065,000,000 | 107,705,000,000 | 99,131,000,000 | 106,410,000,000 | 114,638,000,000 | 116,045,000,000 |
| Stockholders' equity |  | 13,711,000,000 | 41,028,000,000 | 45,338,000,000 | 50,321,000,000 | 47,112,000,000 | 44,675,000,000 | 46,223,000,000 | 41,033,000,000 | 41,713,000,000 |
| Cash and cash equivalents | 3,185,000,000 | 2,972,000,000 | 3,855,000,000 | 4,619,000,000 | 10,182,000,000 | 5,081,000,000 | 5,924,000,000 | 7,822,000,000 | 7,550,000,000 | 7,676,000,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  |  |  |  |  |  |  | 2.64% | 1.39% | 2.17% |
| Operating margin | 7.75% | 9.43% | 8.55% | 5.26% | 5.08% | 4.56% | 4.68% | 4.37% | 3.81% | 3.35% |
| Return on equity |  |  |  |  |  |  |  | 11.17% | 8.37% | 14.28% |
| Return on assets |  |  |  |  |  |  |  | 3.38% | 2.20% | 3.77% |
| Liabilities / equity |  | 3.50 | 2.73 | 2.43 | 2.09 | 2.29 | 2.22 | 2.30 | 2.79 | 2.78 |
| Current ratio |  | 0.85 | 0.64 | 0.74 | 0.77 | 0.83 | 0.73 | 0.77 | 0.84 | 0.85 |

## As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-07-30. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001739940.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | 8.97 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | 4.24 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | 4.92 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 49,048,000,000 | 1,449,000,000 | 4.74 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 51,114,000,000 | 1,107,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 57,255,000,000 | -212,000,000 | -0.97 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 60,523,000,000 | 1,629,000,000 | 5.45 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 63,694,000,000 | 825,000,000 | 2.63 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 65,649,000,000 | 1,536,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 65,502,000,000 | 1,409,000,000 | 4.85 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 67,178,000,000 | 1,632,000,000 | 5.71 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 69,748,000,000 | 1,973,000,000 | 6.98 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 72,472,000,000 | 1,274,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 68,494,000,000 | 1,861,000,000 | 6.26 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 71,668,000,000 | 1,875,000,000 | 6.29 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from CI's latest 10-K: [/company/CI/business/](/company/CI/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from CI's latest 10-K: [/company/CI/risk-factors/](/company/CI/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1739940/000173994026000065/ci-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-07-30
Report date: 2026-06-30

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to provide information to assist you in better understanding and evaluating our financial condition as of June 30, 2026 compared with December 31, 2025 and our results of operations for the three and six months ended June 30, 2026 compared with the same periods last year, and is intended to help you understand the ongoing trends in our business. We encourage you to read this MD&A in conjunction with our Consolidated Financial Statements included in Part I, Item 1 in this Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 Form 10-K"). In particular, we encourage you to refer to the "Risk Factors" contained in Part I, Item 1A in our 2025 Form 10-K.

Unless otherwise indicated, financial information in this MD&A is presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"). See Note 2 to the Consolidated Financial Statements in our 2025 Form 10-K for

30

additional information regarding the Company's significant accounting policies and see Note 2 to the Consolidated Financial Statements in this Form 10-Q for updates to those policies resulting from adopting new accounting guidance, if any. The preparation of interim consolidated financial statements necessarily relies heavily on estimates. This and certain other factors call for caution in estimating full-year results based on interim results of operations. In some of our financial tables in this MD&A, we present either percentage changes or "N/M" when those changes are so large as to become not meaningful. Changes in percentages are expressed in basis points ("bps").

In this MD&A, our consolidated measures "adjusted income from operations," earnings per share on that same basis and "adjusted revenues" are not determined in accordance with GAAP and should not be viewed as substitutes for the most directly comparable GAAP measures of "shareholders' net income," "earnings per share" and "total revenues." We also use pre-tax adjusted income (loss) from operations and adjusted revenues to measure the results of our segments.

The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability. We define adjusted income (loss) from operations as shareholders' net income (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income. See the below Financial Highlights section for a reconciliation of consolidated adjusted income from operations to shareholders' net income.

The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See the below Financial Highlights section for a reconciliation of consolidated adjusted revenues to total revenues.

See Note 15 to the Consolidated Financial Statements for additional discussion of these metrics and a reconciliation of income (loss) before income taxes to pre-tax adjusted income (loss) from operations, as well as a reconciliation of Total revenues to adjusted revenues. Note 15 to the Consolidated Financial Statements also explains that segment revenues include both external revenues and sales between segments that are eliminated in Corporate. Ratios presented in the segment discussion exclude the same items as adjusted revenues and pre-tax adjusted income (loss) from operations.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy, and strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas and the impact of developing inflationary and interest rate pressures; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions and their expected benefits; and other statements regarding The Cigna Group's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to manage health care costs and respond to price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; our ability to compete effectively, differentiate our products and services from those of our competitors and adapt to changes in an evolving and rapidly changing industry; our ability to develop and effectively implement products and services to improve the accessibility, affordability and transparency of health care; changes in drug pricing or industry pricing benchmarks; our ability to maintain relationships with one or

31

more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in government-sponsored programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy, security and data laws, regulations and standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations which could lead to an impairment charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in Part I, Item 1A - "Risk Factors" in our 2025 Form 10-K, discussed in Part II, Item 7 - "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2025 Form 10-K, and as described from time to time in our future reports filed with the Securities and Exchange Commission.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

32

EXECUTIVE OVERVIEW

The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. For further information on our business and strategy, see Part I, Item 1 - "Business" in our 2025 Form 10-K.

Financial Highlights

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1739940/000173994026000006/ci-20251231.htm
Complete FY 2025 MD&A: /company/CI/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-02-26
Report date: 2025-12-31

Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to provide information to assist you in better understanding and evaluating the financial condition of The Cigna Group as of December 31, 2025 compared with December 31, 2024 and our results of operations for 2025 compared with 2024 and 2023 and is intended to help you understand the ongoing trends in our business. For comparisons of our results of operations for 2024 compared with 2023, please refer to the previously filed MD&A included in Part II, Item 7 of our Form 10-K for the year ended December 31, 2024. We encourage you to read this MD&A in conjunction with our Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K ("Form 10-K") and the "Risk Factors" contained in Part I, Item 1A of this Form 10-K.

Unless otherwise indicated, financial information in this MD&A is presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"). See Note 2 to the Consolidated Financial Statements in this Form 10-K for additional information regarding the Company's significant accounting policies. In some of our financial tables in this MD&A, we present either percentage changes or "N/M" when those changes are so large as to become not meaningful. Changes in percentages are expressed in basis points ("bps").

In this MD&A, our consolidated measures "adjusted income from operations," earnings per share on that same basis and "adjusted revenues" are not determined in accordance with GAAP and should not be viewed as substitutes for the most directly comparable GAAP measures of "shareholders' net income," "earnings per share" and "total revenues." We also use pre-tax adjusted income (loss) from operations and adjusted revenues to measure the results of our segments.

The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability. We define adjusted income (loss) from operations as shareholders' net income (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income. See the below Financial Highlights section for a reconciliation of consolidated adjusted income from operations to shareholders' net income.

The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future

36

underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See the below Financial Highlights section for a reconciliation of consolidated adjusted revenues to total revenues.

See Note 23 to the Consolidated Financial Statements for additional discussion of these metrics and a reconciliation of income (loss) before income taxes to pre-tax adjusted income (loss) from operations, as well as a reconciliation of Total revenues to adjusted revenues. Note 23 to the Consolidated Financial Statements also explains that segment revenues include both external revenues and sales between segments that are eliminated in Corporate. Ratios presented in the segment discussion exclude the same items as adjusted revenues and pre-tax adjusted income (loss) from operations.

EXECUTIVE OVERVIEW

The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. For further information on our business and strategy, see Part I, Item 1 - "Business" of this Form 10-K.

Financial Highlights

[[GREPCENT_TABLE]]
[["Consolidated Results of Operations (GAAP basis)"],["","","","","","","","","For the Years Ended December 31,","","Change","Change"],["(Dollars in millions)","","","","","","","","2025","2024","2023","2025 vs. 2024","2024 vs. 2023"],["Pharmacy revenues","","","","","","","","$","216,672","","","$","185,362","","","$","137,243","","","$","31,310","","","17","","%","$","48,119","","","35","","%"],["Premiums","","","","","","","","40,261","","","45,996","","","44,237","","","(5,735)","","","(12)","","","1,759","","","4"],["Fees and other revenues","","","","","","","","16,921","","","14,790","","","12,619","","","2,131","","","14","","","2,171","","","17"],["Net investment income","","","","","","","","1,046","","","973","","","1,166","","","73","","","8","","","(193)","","","(17)"],["Total revenues","","","","","","","","274,900","","","247,121","","","195,265","","","27,779","","","11","","","51,856","","","27"],["Pharmacy and other service costs","","","","","","","","214,991","","","182,509","","","133,801","","","32,482","","","18","","","48,708","","","36"],["Medical costs and other benefit expenses","","","","","","","","34,349","","","38,648","","","36,287","","","(4,299)","","","(11)","","","2,361","","","7"],["Selling, general and administrative expenses","","","","","","","","14,617","","","14,844","","","14,822","","","(227)","","","(2)","","","22","","","\u2014"],["Amortization of acquired intangible assets","","","","","","","","1,743","","","1,703","","","1,819","","","40","","","2","","","(116)","","","(6)"],["Total benefits and expenses","","","","","","","","265,700","","","237,704","","","186,729","","","27,996","","","12","","","50,975","","","27"],["Income from operations","","","","","","","","9,200","","","9,417","","","8,536","","","(217)","","","(2)","","","881","","","10"],["Interest expense and other","","","","","","","","(1,408)","","","(1,435)","","","(1,446)","","","27","","","(2)","","","11","","","(1)"],["Net gain (loss) on sale of businesses","","","","","","","","13","","","24","","","(1,499)","","","(11)","","","(46)","","","1,523","","","N/M"],["Net investment losses","","","","","","","","(24)","","","(2,737)","","","(78)","","","2,713","","","(99)","","","(2,659)","","","N/M"],["Income before income taxes","","","","","","","","7,781","","","5,269","","","5,513","","","2,512","","","48","","","(244)","","","(4)"],["Total income taxes","","","","","","","","1,493","","","1,491","","","141","","","2","","","\u2014","","","1,350","","","N/M"],["Net income","","","","","","","","6,288","","","3,778","","","5,372","","","2,510","","","66","","","(1,594)","","","(30)"],["Less: Net income attributable to noncontrolling interests","","","","","","","","331","","","344","","","208","","","(13)","","","(4)","","","136","","","65"],["Shareholders' net income","","","","","","","","$","5,957","","","$","3,434","","","$","5,164","","","$","2,523","","","73","","%","$","(1,730)","","","(34)","","%"],["Consolidated effective tax rate","","","","","","","","19.2","","%","28.3","","%","2.6","","%","","","(910)","","bps","","","2,570","","bps"],["Medical customers (in thousands)","","","","","","","","18,118","","","19,147","","","19,780","","","(1,029)","","","(5)","","%","(633)","","","(3)","","%"]]
[[/GREPCENT_TABLE]]

37

[[GREPCENT_TABLE]]
[["","Reconciliation of Shareholders' Net Income (GAAP) to Adjusted Income from Operations"],["","","","","","","","","","For the Years Ended December 31,"],["","","","","","","","2025","","2024","","2023"],["","(In millions)","","","","","","","","Pre-tax","After-tax","","Pre-tax","After-tax","","Pre-tax","After-tax"],["","Shareholders' net income","","","","","","","","","$","5,957","","","","$","3,434","","","","$","5,164"],["","Adjustments to reconcile to adjusted income from operations"],["","Net investment (gains) losses (1)","","","","","","","","$","(225)","","(90)","","","$","2,533","","2,529","","","$","135","","114"],["","Amortization of acquired intangible assets","","","","","","","","1,743","","1,325","","","1,703","","1,347","","","1,819","","1,413"],["","Special items"],["","Strategic optimization program","","","","","","","","749","","565","","","\u2014","","\u2014","","","\u2014","","\u2014"],["","Deferred tax expenses (benefits), net","","","","","","","","\u2014","","427","","","\u2014","","84","","","\u2014","","(1,071)"],["","Integration and transaction-related costs","","","","","","","","327","","247","","","275","","211","","","45","","35"],["","(Benefits) charges associated with litigation matters","","","","","","","","(17)","","(13)","","","\u2014","","\u2014","","","201","","171"],["","Net (gain) loss on sale of businesses","","","","","","","","(13)","","(404)","","","(24)","","(2)","","","1,499","","1,429"],["","Impairment of dividend receivable","","","","","","","","\u2014","","\u2014","","","182","","138","","","\u2014","","\u2014"],["","Charge for organizational efficiency plan","","","","","","","","\u2014","","\u2014","","","\u2014","","\u2014","","","252","","193"],["","Total special items","","","","","","","","$","1,046","","822","","","$","433","","431","","","$","1,997","","757"],["","Adjusted income from operations","","","","","","","","","$","8,014","","","","$","7,741","","","","$","7,448"]]
[[/GREPCENT_TABLE]]

(1)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/CI/mda/fy2025/
All MD&A years: /company/CI/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/CI/mda/fy2024/): filed 2025-02-27; accession 0001739940-25-000009 (https://www.sec.gov/Archives/edgar/data/1739940/000173994025000009/ci-20241231.htm)
- [FY 2023 MD&A](/company/CI/mda/fy2023/): filed 2024-02-29; accession 0001739940-24-000005 (https://www.sec.gov/Archives/edgar/data/1739940/000173994024000005/ci-20231231.htm)
- [FY 2022 MD&A](/company/CI/mda/fy2022/): filed 2023-02-23; accession 0001739940-23-000008 (https://www.sec.gov/Archives/edgar/data/1739940/000173994023000008/ci-20221231.htm)
- [FY 2021 MD&A](/company/CI/mda/fy2021/): filed 2022-02-24; accession 0001739940-22-000007 (https://www.sec.gov/Archives/edgar/data/1739940/000173994022000007/ci-20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 6324 Hospital & Medical Service Plans) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [PCEPI](/indicator/PCEPI/): Personal Consumption Expenditures: Chain-type Price Index

Macro-to-micro threads including this sector: [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/CI.md · JSON record: /company/CI.json · verified financials: /company/CI/financials.json / /company/CI/financials.csv · machine TOC for the whole site: /llms.txt